Clinical trials: PD-1 Inhibitors
Stomach Neoplasms
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
Gastric cancer is one of the most common malignant tumors of the digestive tract. Gastric cancer patients diagnosed for the first time in China have a higher proportion of advanced stages and a higher postoperative metastasis…
- Trial name
- NCT04694183
- Testing
- Camrelizumab, S-1, Oxaliplatin
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Quan Wang
Hepatocellular Cancer
Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib
PD-1 inhibitors have become the standard treatment for advanced hepatocellular cancer, while targeted drugs such as sorafenib and lenvatinib are the first-line standard treatment for hepatocellular cancer.
- Trial name
- NCT05453383
- Testing
- Anlotinib;Toripalimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shen Feng
Immune Checkpoint Inhibitors, Liver Injury
A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients
The goal of this observational study is to investigate the risk factors of PD-1/PD-L1 inhibitor-associated liver injury, to construct a prediction model for the occurrence of liver injury.
- Trial name
- NCT06402981
- Testing
- High risk prediction model for liver injury
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Zhejiang University
Oropharyngeal Squamous Cell Carcinoma (SCC)
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
Background: Cancers in and around the mouth associated with human papilloma virus (HPV) are common. Two treatments (the drug pembrolizumab and the HPV vaccine PRGN-2009) have been shown to work well when used individually against…
- Trial name
- NCT05996523
- Testing
- PRGN-2009, Pembrolizumab, EKG
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms Malignant
A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
This is a study to assess the safety and efficacy of CXD101 in combination with the PD-1 Inhibitor Nivolumab in patients with metastatic, previously-treated, Microsatellite-Stable (MSS) Colorectal Carcinoma (CRC).
- Trial name
- CAROSELL (NCT03993626)
- Testing
- CXD101 in Combination With Nivolumab
- Where
- United Kingdom
- Volunteers
- 55 people
- Sponsor
- Celleron Therapeutics Ltd.
Unresectable Cutaneous Melanoma
Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refractory unresectable or metastatic cutaneous melanoma.
- Trial name
- MORALE-MM (NCT07631325)
- Testing
- Axelopran, Nivolumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- John Kirkwood
Cancer, Lung Cancer
Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors
The recent introduction of anti-PD-1 (nivolumab and pembrolizumab) and anti- PD-L1 (atezolizumab, durvalumab, avelumab) immune checkpoint inhibitors revolutionized oncological guidelines.
- Conditions
- Cancer, Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- ICI-DISCOVER (NCT04268368)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Università Politecnica delle Marche
Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
PIVOT study is a multicenter, phase I/II clinical study designed to evaluate induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in patients with unresectable locally advanced…
- Conditions
- Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC
- Trial name
- NCT07632365
- Testing
- Induction chemoimmunotherapy, Concurrent chemoradiotherapy (cCRT), consolidation immunotherapy
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Shanghai Chest Hospital
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
This phase I trial studies the side effects and best dose of COH06 with or without atezolizumab in patients with non-small cell lung cancer previously treated with PD-1 and/or PD-L1 immune checkpoint inhibitors that has spread to…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma
- Trial name
- NCT05334329
- Testing
- Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Irvine
Advanced Solid Tumors
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of EVER4010001 in combination with Pembrolizumab in Patients with Advanced Solid Tumors.
- Trial name
- NCT04699643
- Testing
- EVER4010001
- Where
- China
- Volunteers
- 80 people
- Sponsor
- EverNov Medicines (Zhuhai Hengqin) Co., Ltd
Stage IV NSCLC, NSCLC
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.
- Conditions
- Stage IV NSCLC, NSCLC, Immunotherapy, Fasting Mimicking Diet
- Trial name
- Stage IV NSCLC (NCT06671613)
- Testing
- FMD, Regular Diet Plus FMD
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- VA Office of Research and Development
Rectal Cancer
Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer
This is a single-arm, prospective, multicenter study evaluating a novel neoadjuvant treatment strategy for patients with early, mid-low rectal adenocarcinoma that is microsatellite stable (MSS).
- Trial name
- mRCAT-E (NCT07068763)
- Testing
- Lymph-node-sparing short-course radiotherapy, Capecitabine, PD-1/CTLA-4 inhibitor (Aiparolitoworixureli injection)
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sir Run Run Shaw Hospital
Grade I Meningioma, Adult, Grade II Meningioma, Adult
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
This phase II trial studies the effect of stereotactic radiosurgery and pembrolizumab in treating patients with meningioma that has come back (recurrent).
- Conditions
- Grade I Meningioma, Adult, Grade II Meningioma, Adult, Grade III Meningioma, Adult, Recurrent Meningioma
- Trial name
- NCT04659811
- Testing
- Pembrolizumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Nancy Ann Oberheim Bush, MD
HNSCC, PD-1
PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)
Head and neck malignant tumors rank as the sixth most common type of malignancy worldwide, with approximately 90% being squamous cell carcinoma (Head and Neck Squamous Cell Carcinoma, HNSCC).
- Conditions
- HNSCC, PD-1, Radiotherapy
- Trial name
- NCT07090707
- Testing
- PD-1inhibitor, radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
This is a multicenter, open-label, phase Ib/II study evaluating tislelizumab in combination with zeprumetostat (SHR2554) in patients with relapsed or refractory NK/T-cell lymphoma after at least one prior asparaginase-based…
- Conditions
- Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma, Relapsed or Refractory NK/T-Cell Lymphoma
- Trial name
- EpiRev-NKT (NCT07502768)
- Testing
- Tislelizumab, Zeprumetostat
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Rong Tao
Esophageal Squamous Cell Carcinoma
Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and paclitaxel as neoadjuvant treatment in participants with locally advanced esophageal…
- Trial name
- HYPERION (NCT05281003)
- Testing
- Pembrolizumab, Paclitaxel, Cisplatin
- Where
- 2 sites in China
- Volunteers
- 128 people
- Sponsor
- Fudan University
Immune Checkpoint Inhibitors, Lung Cancer
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
the purpose of this study is to identify multi-dimensional immunological biomarkers including cytokines, autoantibodies, and immune cell subtypes of immune-related adverse events (primary) and prognosis(secondary) in the…
- Trial name
- NCT05288569
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Lung Cancer
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in…
- Trial name
- NCT03322566
- Testing
- Pembrolizumab, Epacadostat, Platinum-based chemotherapy
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 233 people
- Sponsor
- Incyte Corporation
Cholangiocarcinoma, Hilar Cholangiocarcinoma
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
This is a phase II, single-arm, prospective clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy combining stereotactic body radiotherapy (SBRT), GP chemotherapy (gemcitabine and…
- Conditions
- Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer
- Trial name
- NCT07030140
- Testing
- Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Jinbo Yue
Pancreatic Adenocarcinoma
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
This is a study of the combination of 9 ING-41 (elraglusib) and retifanlimab plus mFOLFIRINOX in patients with pancreatic cancer without prior systemic therapy for advanced disease.
- Trial name
- RiLEY (NCT06896188)
- Testing
- Retifanlimab, Chemotherapy, 9-ING-41
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Anwaar Saeed